Add to my selection

TEVIMBRA (tislélizumab)

Medicine - Posted on Nov 21 2025

Active substance (DCI)

tislélizumab

history (3)

10/22/25

TEVIMBRA (tislélizumab) - Metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma

Summary of opinion Favourable opinion for reimbursement in the MA indications, i.e.: “TEVIMBRA, in combination with platinum...

CAV :
54321

icône flèche
11/6/24

TEVIMBRA (tislelizumab) - Oesophageal squamous cell carcinoma

Summary of opinion Unfavourable opinion for reimbursement in the indication “TEVIMBRA as monotherapy is indicated for the tr...

CAV :
54321

icône flèche
9/19/24

TEVIMBRA (tislélizumab) - Carcinome épidermoïde de l’oesophage

Autorisation d’accès précoce refusée à la spécialité TEVIMBRA (tislélizumab) dans l’indication « en monothérapie dans le tra...

icône flèche

Technical information

ATC code

L01FF09

Manufacturer

BEONE MEDICINES FRANCE

Presentation

TEVIMBRA 100 mg, solution à diluer pour perfusion
1 flacon en verre de 10 mL (CIP : 34009 551 016 2 8)
2 (2 x 1) flacons en verre de 10 mL (CIP : 34009 551 016 3 5)

All our publications

Digestive system cancers

Drug therapy

My account

You do not have a saved search

TEVIMBRA (tislélizumab)

TEVIMBRA (tislélizumab) - Metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma

TEVIMBRA (tislelizumab) - Oesophageal squamous cell carcinoma

TEVIMBRA (tislélizumab) - Carcinome épidermoïde de l’oesophage

Follow us :